<DOC>
	<DOCNO>NCT02555761</DOCNO>
	<brief_summary>This post-marketing surveillance study assess safety efficacy Lastacaft® Opthalmic Solution 0.25 % ( Alcaftadine ) prevention itch associate Allergic Conjunctivitis prescribe standard care clinical practice Korea .</brief_summary>
	<brief_title>Safety Efficacy Lastacaft® Prevention Itching Associated With Allergic Conjunctivitis Korea</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Alcaftadine</mesh_term>
	<criteria>Patients itch associate allergic conjunctivitis . Patients hypersensitivity Lastacaft® component .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>